To test this hypothesis, we first treated 4 different KMT2A-R ALL cell lines either with vehicle control, EHT1610, the MEK1/2 inhibitor trametinib, or a combination of both drugs (Fig. 5C). This evidence concerns the gene MAP2K1 and acute lymphoblastic leukemia.